Structure Therapeutics (GPCR) Research & Development (2022 - 2026)

Structure Therapeutics' Research & Development history runs 5 years deep, the most recent figure standing at $66.5 million for Q1 2026.

• In Q1 2026, Research & Development rose 55.15% year-over-year to $66.5 million; the TTM figure through Mar 2026 stood at $248.9 million (up 89.99% YoY), while the FY2025 annual figure was $225.3 million, up 107.01% from the prior year.
• Research & Development was $66.5 million for Q1 2026 at Structure Therapeutics, down from $68.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $68.7 million in Q4 2025 to a low of $8.4 million in Q4 2022.
• Historically, Research & Development has averaged $29.8 million across 5 years, with a median of $20.7 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Research & Development advanced 13.6% in 2024, then surged 148.12% in 2025.
• A 5-year view of Research & Development shows it stood at $8.4 million in 2022, then soared by 139.74% to $20.0 million in 2023, then jumped by 67.08% to $33.5 million in 2024, then surged by 105.12% to $68.7 million in 2025, then fell by 3.18% to $66.5 million in 2026.
• The last three Research & Development figures came in at $66.5 million (Q1 2026), $68.7 million (Q4 2025), and $59.0 million (Q3 2025), per Business Quant data.